OR WAIT 15 SECS
The global Alzheimer’s Disease (AD) market, worth $2.9 billion in 2016, is predicted to reach $14.8 billion by 2026 across US, Japan, France, Germany, Italy, Spain, and the UK (the seven major markets), according to business information and analytics company GlobalData. This shows an annual growth rate of 17.5%.
The company’s latest report focuses on the considerable landscape change that the AD market is expected to experience in the next 10 years. The key driver in market growth will be the introduction of 20 new drug candidates, some of which have shown potential to prevent or slow down the progression of AD.
These include passive immunotherapies aducanumab, gantenerumab, and crenezumab, which are expected to have significant uptake in the seven major markets.
The clinical unmet needs for AD include a curative treatment or DMT, accurate diagnostic tests that can be applied with relative ease, biomarkers for assessing the treatment response, patient classification and determination of risk, and healthcare improved control of the primary cognitive symptoms of the disease.